H-VVGAVGVGK^-OH

Ref. 3D-PP48518

Produktinformation

• Name: H-VVGAVGVGK^-OH

Beschreibung

Peptide H-VVGAVGVGK^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VVGAVGVGK^-OH include the following: The common neoantigens in colorectal cancer are predicted and validated to be presented or immunogenic Z Liang, L Qin, L Chen, W Li, C Chen, Y Huang - bioRxiv, 2019 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/682617.abstract Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. S Jung, HJ Schluesener - The Journal of experimental medicine, 1991 - rupress.orghttps://rupress.org/jem/article-abstract/173/1/273/24329 Abstract C004: TCRs directed to mutant KRAS display distinct antigen recognition motifs and minimal cross-reactivity to non-cognate antigens RB Nadler, A Bear , RH Vonderheide, GP Linette - Cancer Research, 2022 - AACRhttps://aacrjournals.org/cancerres/article/82/22_Supplement/C004/710393 Identification of T-cell receptors targeting KRAS-mutated human tumors QJ Wang, Z Yu, K Griffith, K Hanada, NP Restifo - Cancer immunology , 2016 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/4/3/204/468486 Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy N Levin , BC Paria, NR Vale, R Yossef , FJ Lowery - Clinical Cancer , 2021 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/27/18/5084/671639 Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen M Zhang, W Xu, L Luo, F Guan, X Wang, P Zhu - Communications , 2024 - nature.comhttps://www.nature.com/articles/s42003-024-06209-2 Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy M Angelova , P Charoentong , H Hackl , ML Fischer - Genome biology, 2015 - Springerhttps://link.springer.com/article/10.1186/s13059-015-0620-6 Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen KM Wright, SR DiNapoli, MS Miller - Nature , 2023 - nature.comhttps://www.nature.com/articles/s41467-023-40821-w Systematic discovery of Neoepitope-HLA pairs for neoantigens shared among patients and tumor types HR Gurung , AJ Heidersbach, M Darwish - Nature , 2023 - nature.comhttps://www.nature.com/articles/s41587-023-01945-y Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations GP Linette, AS Bear , BM Carreno - Clinical Cancer Research, 2024 - AACRhttps://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-23-1212/733759 KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors D Lu, Y Chen, M Jiang, J Wang, Y Li, K Ma - Nature , 2023 - nature.comhttps://www.nature.com/articles/s41467-023-42010-1 åŞºÀºŜÀœ“细ڃşçªå˜Ê•°Ê®åº“筛选å ç–«åŜŞÊ€§ç»“盎ڂ ç™Œé«˜é¢‘Ê–°ÊŠ—åŜŞçš„Ê–¹Ê³• çhttp://www.chinagene.cn/EN/Y2020/V42/I6/599 Generating optimal-affinity T cell receptors targeting the shared neoantigen KRAS G12V using the humanized TCR transgenic mouse platform HuTCR A Leliavski, L Knackstedt, J Oduro, C Selck - Cancer , 2022 - t-knife.comhttps://www.t-knife.com/file.cfm/47/docs/t-knife_aacr2022_poster_3052.pdf

• Marke: Biosynth